<DOC>
	<DOCNO>NCT01223378</DOCNO>
	<brief_summary>The objective clinical investigation determine effective drug concentration ( ) BOL-303259-X reduction IOP order support clinical development appropriate dose regard efficacy , ocular systemic safety .</brief_summary>
	<brief_title>Study Comparing Safety Efficacy BOL-303259-X Latanoprost Subjects With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subjects must diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OH ) one eye . Subjects know hypersensitivity contraindication latanoprost ingredient study drug . Subjects close barely open anterior chamber angle history acute angle closure either eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>